InSense Medical Ltd

A novel technology that lets you breathe without your lungs

The OXYLINK is a smart device that provides patients suffering from respiratory insufficiency almost immediate relief. Patiets receive a safe and more effective treatment without the complications associated with mechanical ventilation. The patient is treated while awake without the need for being placed into a medically induced coma and without neuromuscular blocking agents. InSense has performed several studies including on a 30kg swine, where oxygen levels were increased and carbon dioxide levels were reduced. The company is undergoing a Series A Round of $3.5m, with an FDA IDE submission within 12 months. Based on U.S FDA legal and consulting companies, InSense will attain FDA Certification within 36 months, fast lane De Novo Program.

Stage

Series A

Markets

BioTech, Healthcare, Respiratory Care

Seeking

$3.5M